1. Introduction {#sec1-jcm-09-00543}
===============

The Maastricht V/Florence Consensus Report issued by the European *Helicobacter* Study Group in 2017 recommends eradication of *Helicobacter pylori* (*H. pylori*) for patients with peptic ulcer disease, autoimmune thrombocytopenia, chronic urticaria, iron deficiency anemia, gastric mucosa associated-lymphoid tissue lymphoma, atrophic gastritis, intestinal metaplasia, and functional dyspepsia \[[@B1-jcm-09-00543],[@B2-jcm-09-00543],[@B3-jcm-09-00543],[@B4-jcm-09-00543],[@B5-jcm-09-00543],[@B6-jcm-09-00543]\]. In general, although first-line *H. pylori* eradication triple therapy consisting of a proton pump inhibitor (PPI) and two kinds of antimicrobial agents (e.g., clarithromycin (CAM), amoxicillin (AMPC), metronidazole (MNZ), or levofloxacin) is practiced worldwide, appropriate eradication with high efficacy and safety remains somewhat elusive.

In patients living in areas with high CAM resistance rates (\> 15%), such as Japan, the Maastricht V/Florence Consensus Report suggests that when bacterial culture and sensitivity testing are not performed before eradication therapy, first-line triple eradication therapy with PPI and CAM should not be used; rather, bismuth quadruple (PPI, bismuth, tetracycline, and MNZ) or non-bismuth quadruple, concomitant (PPI, AMPC, CAM and nitroimidazole/MNZ) therapies are recommended as the first-line therapy \[[@B1-jcm-09-00543]\].

From 1990 to 2000, eradication rates achieved in Japan using CAM-containing triple therapy ranged from approximately 85%--91% \[[@B7-jcm-09-00543]\]. This rate subsequently decreased with the emergence of CAM-resistant strains \[[@B8-jcm-09-00543],[@B9-jcm-09-00543],[@B10-jcm-09-00543],[@B11-jcm-09-00543]\], and recent patients with these strains have experienced marked decreases, to 10%--30% \[[@B12-jcm-09-00543],[@B13-jcm-09-00543]\]. The most recently measured frequencies of CAM-resistant strains in Japan and Europe exceed 35% and 20%, respectively \[[@B7-jcm-09-00543],[@B13-jcm-09-00543],[@B14-jcm-09-00543],[@B15-jcm-09-00543]\]. This in turn necessitates the careful selection of eradication regimens based on individual antibiotic resistance to *H. pylori* and/or known regional characteristics \[[@B1-jcm-09-00543],[@B16-jcm-09-00543]\]. It is recommended that CAM sensitivity testing be performed when a standard CAM-containing triple regimen (i.e., PPI, AMPC and CAM regimen (PAC regimen)) is considered for first-line therapy, except in populations or regions with well-documented low CAM resistance (\<15%) \[[@B1-jcm-09-00543]\]. In addition, in geographical areas where MNZ resistance is almost negligible, replacing CAM with MNZ in triple therapy (i.e., PPI, AMPC and MNZ regimen (PAM regimen)) shows excellent cure rates \[[@B17-jcm-09-00543],[@B18-jcm-09-00543]\]. The Maastricht V/Florence Consensus Report currently recommends the PAM regimen in settings with high CAM resistance.

Since 2013, *H. pylori* eradication therapy has been approved for all patients in Japan with *H. pylori*-related gastritis confirmed by endoscopy \[[@B19-jcm-09-00543]\]. However, the official first-line eradication regimen is the PAC regimen and the second-line regimen is PAM, irrespective of whether the patient is infected with a CAM- or MNZ-resistant strain of *H. pylori*. Many randomized control trials (RCTs) have compared the efficacy of PAC and PAM, but the year-by-year changes in the incidence rates of antimicrobial resistance mandate that the efficacy of these regimens be periodically reevaluated. In addition, although international guidelines suggest that the selection of treatment regimen be performed based on susceptibility to the antimicrobial agents involved \[[@B1-jcm-09-00543]\], no meta-analysis has yet investigated the association of the efficacy of PAC vs. PAM therapy and geographical area based on incidence rates of antimicrobial agent resistance.

Here, we performed a meta-analysis to reevaluate the efficacy and safety of PAC and PAM therapies in relation to CAM/MNZ resistance-defined location.

2. Materials and Methods {#sec2-jcm-09-00543}
========================

2.1. Search Strategy and Inclusion Criteria {#sec2dot1-jcm-09-00543}
-------------------------------------------

In this meta-analysis, we compared eradication rates between CAM-containing PAC therapy and MNZ-containing PAM therapy (each given over 7--14 days) as first-line therapy by conducting a search of the medical literature using data of randomized control trials.

Three researchers (MM, MS and HM) independently searched both the PubMed and Cochrane Library databases using the terms "*Helicobacter pylori*," "eradication," and "triple" and reviewed titles and abstracts for all potential studies ([Figure 1](#jcm-09-00543-f001){ref-type="fig"}).

The inclusion criteria were:RCTs published up to December 2018;Studies comparing eradication rates of PAC therapy with those of PAM therapy for *H. pylori* infection;Studies performed as first-line treatment;Studies that detected *H. pylori* infection by one or more tests (urea breath test, histology, rapid urease test, stool monoclonal antigen or culture);Studies checking eradication outcome ≥ 4 weeks after eradication therapy; andStudies written in English.

Exclusion criteria were:Studies performed with regimens other than PAC or PAM regimens, andStudies with treatment periods \> 14 days.

Author names, publication year, country where the study was conducted, number of patients, eradication rate for each regimen, patient characteristics (sex and age), and incidence of adverse events (e.g., diarrhea, skin rash, dysgeusia, and nausea) were extracted from each study.

2.2. Statistical Analysis {#sec2dot2-jcm-09-00543}
-------------------------

First, a meta-analysis of RCTs comparing the cure rates and adverse events of PAC versus PAM therapy was performed. For each comparison, intention-to-treat (ITT) and per-protocol (PP) analysis of eradication rates were calculated. Relative risks (RR) and their corresponding 95% confidence intervals (CIs) were used to summarize the effect of each comparison tested using random-effect models, and the calculated results were confirmed in a fixed-effects model as well \[[@B20-jcm-09-00543],[@B21-jcm-09-00543],[@B22-jcm-09-00543]\]. We also divided studies into four groups based on CAM (\< 15% or ≥ 15%) and MNZ resistance rates (\< 15% or ≥ 15%) in the country where the study was conducted ([Table S1](#app1-jcm-09-00543){ref-type="app"}) \[[@B10-jcm-09-00543],[@B11-jcm-09-00543],[@B23-jcm-09-00543],[@B24-jcm-09-00543],[@B25-jcm-09-00543],[@B26-jcm-09-00543]\].

Potential study bias in each study was evaluated by funnel plots. Heterogeneity was evaluated by the *I^2^* value and Cochran's Q. The *I^2^* value was used to assess the heterogeneity of the studies as follows: 0%--39%, low heterogeneity; 40%--74%, moderate heterogeneity; and 75%--100%, high heterogeneity.

All meta-analyses were conducted using open-source statistical software (Review Manager Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). All *p* values are two-sided, and *p* \< 0.05 was considered statistically significant. Calculations were performed using commercial software (SPSS version 20, IBM Inc; Armonk NY, USA)

3. Results {#sec3-jcm-09-00543}
==========

3.1. Literature Search and Data Extraction {#sec3dot1-jcm-09-00543}
------------------------------------------

The search strategy yielded 2543 potentially eligible studies from the PubMed and Cochrane Library databases and 22 studies by hand-search through other sources and papers ([Figure 1](#jcm-09-00543-f001){ref-type="fig"}). Forty studies were selected from the extracted studies. Of those, six studies involved non-PAC and/or non-PAM regimens, three were duplicated studies, two were reviews, and two studies had treatment periods \> 14 days; these were excluded. Ultimately, a total of 27 full articles were assessed for eligibility ([Figure 1](#jcm-09-00543-f001){ref-type="fig"}) \[[@B17-jcm-09-00543],[@B18-jcm-09-00543],[@B23-jcm-09-00543],[@B27-jcm-09-00543],[@B28-jcm-09-00543],[@B29-jcm-09-00543],[@B30-jcm-09-00543],[@B31-jcm-09-00543],[@B32-jcm-09-00543],[@B33-jcm-09-00543],[@B34-jcm-09-00543],[@B35-jcm-09-00543],[@B36-jcm-09-00543],[@B37-jcm-09-00543],[@B38-jcm-09-00543],[@B39-jcm-09-00543],[@B40-jcm-09-00543],[@B41-jcm-09-00543],[@B42-jcm-09-00543],[@B43-jcm-09-00543],[@B44-jcm-09-00543],[@B45-jcm-09-00543],[@B46-jcm-09-00543],[@B47-jcm-09-00543],[@B48-jcm-09-00543],[@B49-jcm-09-00543],[@B50-jcm-09-00543]\] and a total of 4825 patients treated with the PAC vs. PAM regimens for *H. pylori* infection were included in the analysis.

The characteristics of the trials are shown in [Table 1](#jcm-09-00543-t001){ref-type="table"}. Mean patient age ranged from 26--77 years ([Table 1](#jcm-09-00543-t001){ref-type="table"}). Eradication therapy was performed by a regimen including PPI (pantoprazole (40 mg, twice-daily dosing (bid), omeprazole (20 mg, bid), lansoprazole (30 mg, bid), rabeprazole (10 or 20 mg, bid) or esomeprazole (20 mg, bid)) and AMPC (500, 750 or 1,000 mg, bid, or 500 mg, three times daily (tid)). In addition, the PAC therapy used CAM (200, 250, 400, or 500 mg, bid) and the PAM therapy used any imidazole antimicrobial agent (MNZ: 250, 400, 500, or 750 mg bid, or 400 mg tid, or tinidazole, 500 mg bid). Most of the studies administered PAC and PAM therapy for seven days, but two studies used 14 days \[[@B40-jcm-09-00543],[@B50-jcm-09-00543]\] and two used 7--14 days ([Table 1](#jcm-09-00543-t001){ref-type="table"}) \[[@B43-jcm-09-00543],[@B45-jcm-09-00543]\].

Although adherence is important to receive high eradication rates, there is no significant different adherence between the PAC therapy and the PAM therapy in each study ([Table S2](#app1-jcm-09-00543){ref-type="app"}).

3.2. Meta-Analysis for Eradication Rate of PAC vs. PAM Therapy {#sec3dot2-jcm-09-00543}
--------------------------------------------------------------

When all 27 trials were analyzed, the ITT eradication rates of the PAC therapy and PAM therapy groups were 74.8% (1833/2451, 95% confidence interval (CI): 73.0%--76.5%) and 72.5% (1721/2374, 95% CI 70.9%--74.4%) and the PP eradication rates were 81.3% (1823/2242, 95% CI: 79.6%--82.9%) and 78.6% (1705/2168, 95% CI 76.9%--80.4%), respectively (*P* =0.08 and 0.06). Meta-analysis showed that the relative risk (RR) for successful eradication with PAC therapy compared with PAM therapy was 1.13 (95% CI: 0.91--1.39, *p* = 0.27) in the ITT analysis ([Figure 2](#jcm-09-00543-f002){ref-type="fig"}A) and 1.18 (95% CI: 0.90--1.55, *p* = 0.22) in the PP analysis ([Figure 2](#jcm-09-00543-f002){ref-type="fig"}B) in the random-effects model; and 1.07 (95% CI: 0.98--1.17, *p* = 0.14) and 1.11 (95% CI: 0.99--1.24, *p* = 0.08) in the fixed-effects model ([Figure S1A,B](#app1-jcm-09-00543){ref-type="app"}). There was high heterogeneity among these studies (ITT analysis: *p* \< 0.01; *I*^2^ = 75%, the PP analysis: *p* \<0.01; *I*^2^ = 76%). The funnel plot of all included studies showed asymmetry between PAC therapy and PAM therapy ([Figure 3](#jcm-09-00543-f003){ref-type="fig"}).

3.3. Subgroup Analysis of Eradication Rates by Different Geographical Areas Based on Rates of CAM and MNZ Resistance {#sec3dot3-jcm-09-00543}
--------------------------------------------------------------------------------------------------------------------

We assessed resistance to CAM and MNZ using previous studies \[[@B10-jcm-09-00543],[@B11-jcm-09-00543],[@B23-jcm-09-00543],[@B24-jcm-09-00543],[@B25-jcm-09-00543],[@B26-jcm-09-00543]\] ([Table S1](#app1-jcm-09-00543){ref-type="app"}). Twelve studies documented areas with high resistance to both CAM (≥ 15%) and MNZ (≥ 15%) (MNZ-R/CAM-R), namely: China, Korea, Morocco, Poland, Taiwan, Turkey, and the United Kingdom \[[@B28-jcm-09-00543],[@B29-jcm-09-00543],[@B31-jcm-09-00543],[@B32-jcm-09-00543],[@B33-jcm-09-00543],[@B37-jcm-09-00543],[@B38-jcm-09-00543],[@B39-jcm-09-00543],[@B41-jcm-09-00543],[@B42-jcm-09-00543],[@B43-jcm-09-00543],[@B44-jcm-09-00543],[@B46-jcm-09-00543],[@B47-jcm-09-00543],[@B49-jcm-09-00543]\]. Areas with high resistance to MNZ and low resistance to CAM (MNZ-R/CAM-S) included Tunisia, North India, Italy, Germany and Finland, in nine studies \[[@B1-jcm-09-00543],[@B5-jcm-09-00543],[@B8-jcm-09-00543],[@B9-jcm-09-00543],[@B10-jcm-09-00543],[@B13-jcm-09-00543],[@B14-jcm-09-00543],[@B16-jcm-09-00543],[@B27-jcm-09-00543]\]. Japan was classified as an area with low MZN resistance and high CAM resistance (MNZ-S/CAM-R) in four studies \[[@B23-jcm-09-00543],[@B28-jcm-09-00543],[@B31-jcm-09-00543],[@B34-jcm-09-00543],[@B35-jcm-09-00543],[@B36-jcm-09-00543],[@B39-jcm-09-00543],[@B40-jcm-09-00543],[@B46-jcm-09-00543]\]. There was no area with low resistance to both CAM and MNZ.

On analysis of studies from the MNZ-R/CAM-S area, eradication rates for PAC and PAM therapy were 72.9% (481/660, 95% CI: 69.3%--76.2%) and 67.2% (433/644, 95% CI: 63.5%-70.9%), respectively, in the ITT analysis. Meta-analysis showed that the RR for successful eradication by PAC therapy compared to PAM therapy was 1.26 (95% CI: 0.95--1.67, *P* = 0.11) in the random-effects model ([Figure 4](#jcm-09-00543-f004){ref-type="fig"}A), and 1.47 (95% CI: 1.17--1.85, *p* \< 0.01) in the fixed-effects model ([Figure S2A](#app1-jcm-09-00543){ref-type="app"}). There was moderate heterogeneity among these studies (*p* = 0.02; *I*^2^ = 57%).

On analysis of studies from the MNZ-S/CAM-R area, eradication rates were 70.8% (240/339, 95% CI: 65.6%--75.6%) for PAC and 92.5% (347/375, 95% CI: 89.4%--95.0%) for PAM therapy in the ITT analysis. In meta-analysis, the RR for successful eradication with PAC therapy compared to PAM therapy was 0.29 (95% CI: 0.13--0.68, *p* \<0.01) in the random-effects model ([Figure 4](#jcm-09-00543-f004){ref-type="fig"}B) and 0.23 (95% CI: 0.15--0.36, *p* \<0.01) in the fixed-effects model ([Figure S2B](#app1-jcm-09-00543){ref-type="app"}). There was high heterogeneity among these studies (*p* \< 0.01; *I*^2^ = 76%).

In the MNZ-R/CAM-R area, eradication rates were 72.4% (668/923, 95% CI: 69.4%-75.2%) for PAC therapy and 65.3% (610/934, 95% CI 62.2%--68.4%) for PAM therapy in the ITT analysis. The RR of successful eradication of PAC therapy compared to PAM therapy was 1.37 (95% CI: 1.05--1.77, *p* = 0.02) in the random-effects model ([Figure 4](#jcm-09-00543-f004){ref-type="fig"}C) and 1.22 (95% CI: 1.07--1.40, *p* \< 0.01) in the fixed-effects model ([Figure S2C](#app1-jcm-09-00543){ref-type="app"}). There was moderate heterogeneity among these studies (*p* \< 0.01; *I*^2^ = 66%).

The funnel plots of studies from the MNZ-R/CAM-S area ([Figure 5](#jcm-09-00543-f005){ref-type="fig"}A), the MNZ-S/CAM-R area ([Figure 5](#jcm-09-00543-f005){ref-type="fig"}B) and the MNZ-R/CAM-R area ([Figure 5](#jcm-09-00543-f005){ref-type="fig"}C) suggest asymmetry between PAC therapy and PAM therapy.

When we divided studies into different kinds of PPI, PAM therapy had a significantly higher eradication rate compared with the PAC therapy in patients living in the area of MNZ-S/CAM-R. Eradication rates with PAC therapy were \< 75%, and the eradication rate in studies from the MNZ-R/CAM-S area was similar to that with PAM therapy in spite of different kinds of PPI (data not shown). However, because number of studies was small, we could not perform sub-analysis by different treatment duration (seven days and 10/14 days) and different daily dose of drugs (PPI, amoxicillin, clarithromycin and metronidazole).

3.4. Meta-Analysis of the Incidence Rates of Adverse Events from PAC Therapy vs PAM Therapy {#sec3dot4-jcm-09-00543}
-------------------------------------------------------------------------------------------

Nineteen studies (70.4%) provided information on adverse events, namely diarrhea, skin rash, dysgeusia, and nausea ([Table 2](#jcm-09-00543-t002){ref-type="table"}) \[[@B18-jcm-09-00543],[@B23-jcm-09-00543],[@B27-jcm-09-00543],[@B29-jcm-09-00543],[@B31-jcm-09-00543],[@B32-jcm-09-00543],[@B33-jcm-09-00543],[@B34-jcm-09-00543],[@B35-jcm-09-00543],[@B36-jcm-09-00543],[@B37-jcm-09-00543],[@B38-jcm-09-00543],[@B40-jcm-09-00543],[@B42-jcm-09-00543],[@B45-jcm-09-00543],[@B48-jcm-09-00543],[@B49-jcm-09-00543],[@B50-jcm-09-00543]\]. The incidence of adverse events from PAC therapy vs. PAM therapy were 22.8% (308/1351, 95% CI: 20.6%--25.1%) and 22.6% (317/1402, 95% CI 20.4%--24.9%), respectively. There was no difference in the incidence of adverse events between the two regimens (RR: 1.03, 95% CI: 0.91--1.17, *P* = 0.61) in the random-effects model ([Figure 6](#jcm-09-00543-f006){ref-type="fig"}). There was no heterogeneity among these studies (*p* = 0.49; *I*^2^ = 0%).

The incidence rate of diarrhea was similar between PAC therapy (8.9%, 144/1623, 95% CI: 7.5%--10.4%) and PAM therapy (6.9%, 109/1578, 95% CI: 5.7%-8.3%) (RR: 0.84, 95% CI: 0.67--1.05, *p* = 0.13). The incidence rates of skin rash and dysgeusia were also similar. In contrast, the incidence rate of nausea with PAM therapy (5.9%, 78/1324, 95% CI: 4.7%--7.3%) was significantly higher than that with PAC therapy (2.7%, 37/1368, 95% CI: 1.9%--3.7%) (RR: 2.07, 95% CI: 1.42--3.02, *p* \< 0.01).

4. Discussion {#sec4-jcm-09-00543}
=============

This meta-analysis of 27 RCTs reevaluated the efficacy and safety of PAC therapy and PAM therapy. The overall eradication rate for PAC therapy and PAM therapy was 74.8% (95% CI: 73.2%--76.5%) and 72.5% (95% CI: 70.6--74.3), respectively. However, in the sub-analysis, PAM therapy had a significantly higher eradication rate, \> 90%, compared with PAC therapy in patients living in the area of MNZ-S/CAM-R. Therefore, the PAM regimen may be selected for patients living in the MNZ-S/CAM-R area to achieve a high eradication rate. On the other hand, overall eradication rates with PAC therapy were insufficient, \< 75%, and the eradication rate in studies from the MNZ-R/CAM-S area was surprisingly similar to that with PAM therapy. First-line therapy for *H. pylori* eradication should have an eradication rate \> 90% \[[@B51-jcm-09-00543]\]; accordingly, the low rate for PAC therapy (\< 90%) may be insufficient, irrespective of susceptibility to CAM.

4.1. Importance of H. pylori Antimicrobial Agent Resistance {#sec4dot1-jcm-09-00543}
-----------------------------------------------------------

In general, diagnosis and treatment for infectious diseases require culture and sensitivity testing for antimicrobial agents. *H. pylori* is a gram-negative bacterium; the international treatment guidelines for *H. pylori* infection recommend that susceptibility to antimicrobial agents be checked using several tests \[[@B51-jcm-09-00543],[@B52-jcm-09-00543]\]. Culture test and real-time polymerase chain reaction (PCR) methods are generally used to evaluate susceptibility to antimicrobial agents using clinical samples of gastric mucosa, gastric juice, and stool samples \[[@B53-jcm-09-00543],[@B54-jcm-09-00543]\]. Recently, the efficacy of tailored treatment based on sensitivity to CAM (PAC therapy for patients infected with CAM-sensitive strains and PAM therapy for patients infected with CAM-resistant strains) has been shown, with eradication rates \> 90% \[[@B55-jcm-09-00543],[@B56-jcm-09-00543]\]. Although this tailored treatment based on susceptibility to CAM had a high eradication rate, especially in areas with a high incidence rate of CAM-resistant *H. pylori*, tailored treatment for all patients with *H. pylori* infection or all areas/populations in the world is not feasible, due to disadvantages in culture testing and PCR in clinical practice, as we describe below. Collection of biopsy specimens and culture of gastric mucosa via endoscopy increase the risk of hemorrhage, especially in patients taking antithrombotic drugs \[[@B57-jcm-09-00543]\]. Culture is also inconvenient and time consuming. In addition, importantly, when comparing with standard triple therapy, the cost-effectiveness of tailored treatment guided by culture and PCR should be understood. However, because our results showed that the efficacy of PAC and PAM therapies varied among countries depending on the prevalence of CAM- and MNZ-resistant strains, it is also important to clarify changes in the incidence of drug resistance among locations \[[@B10-jcm-09-00543]\].

In this meta-analysis, PAM therapy showed high efficacy in populations in areas with a low incidence of MNZ resistance (i.e., Japan), and would accordingly be recommended as first-line therapy in these populations. Because few areas have low (\< 15%) MNZ resistance, Japan may be distinctive from the perspective of susceptibility to MNZ. Although MNZ is widely used worldwide as a treatment for anaerobic bacteria in both children and adults, the Japanese health insurance system initially approved MNZ for adult trichomoniasis only. Therefore, although the Japanese health insurance system approved second-line PAM therapy for patients with *H. pylori* infection, our findings suggest that PAM be used as first-line therapy. Although a similar susceptibility pattern was not seen, PAM therapy may be effective in regions with low MNZ resistance (\< 20%; i.e., North America \[[@B58-jcm-09-00543]\] or Chile \[[@B59-jcm-09-00543]\]).

Meanwhile, eradication rates with PAC therapy were extremely low not only in areas with CAM/MNZ-double resistant *H. pylori* and but also in CAM-sensitive areas, at only 73% (ITT analysis) and 82% (PP analysis). Although PAC therapy is recommended for regions with CAM resistance rates \< 15%, our present results show that PAC therapy is insufficient as a first-line therapy even in regions with low resistance. What is the reason for this low eradication rate when CAM resistance rate is generally low (\< 15%)? We previously showed high efficacy (\> 90%) in tailored treatment based on susceptibility to CAM \[[@B56-jcm-09-00543]\], and this was also shown in a study from Finland with low CAM resistance (2%), with an eradication rate \> 90% with PAC therapy ([Table S1](#app1-jcm-09-00543){ref-type="app"}) \[[@B23-jcm-09-00543]\]. Thus, we recommend that the country incidence of CAM resistance be re-evaluated when PAC therapy is used, or a decrease in the cut-off value of CAM resistance rate to \< 5--10%. In addition, since the incidence of CAM resistance to *H. pylori* is expected to increase in the future, alternative optimal treatment regimens will be required for patients with *H. pylori* infection living in CAM-R/MNZ-R or CAM-S/MNZ-R areas.

4.2. Alternatives to Triple Therapy {#sec4dot2-jcm-09-00543}
-----------------------------------

Bismuth and non-bismuth quadruple therapies have been recommended as alternative eradication strategies \[[@B1-jcm-09-00543]\]. Bismuth quadruple therapy, consisting of bismuth, tetracycline, metronidazole, and amoxicillin, is traditionally used and is an acceptable therapy worldwide \[[@B60-jcm-09-00543],[@B61-jcm-09-00543]\]. However, meta-analyses comparing it with triple conventional therapy showed that bismuth quadruple therapy offered no advantage over triple therapy in either eradication rate or prevention of adverse events \[[@B62-jcm-09-00543],[@B63-jcm-09-00543],[@B64-jcm-09-00543]\]. In addition, a disadvantage of bismuth quadruple therapy is its more complicated dosing schedule, which makes adherence difficult to maintain. Some countries, such as Japan, France, and Australia, cannot use bismuth preparations due to a lack of approval or availability \[[@B65-jcm-09-00543]\], and the possibility of it becoming a universal treatment may accordingly be low. However, because bismuth quadruple therapy revealed high eradication efficacy in regions with a high incidence of both MNZ and CAM resistance \[[@B66-jcm-09-00543]\], this regimen may be indicated in limited populations (i.e., patients infected with MNZ- and CAM-resistant strains).

Non-bismuth quadruple therapy (concomitant therapy), which consists of a PPI combined with amoxicillin, clarithromycin, and a nitroimidazole bid for 5--10 days, has achieved an eradication rate of 91.7% in patients infected with CAM-sensitive strains \[[@B67-jcm-09-00543]\]. In areas with CAM-S/MNZ-R, this regimen may be optimal \[[@B68-jcm-09-00543]\], as the eradication rate with concomitant therapy in patients with double CAM- and MNZ-resistant strains was only 33.3%--66.7% \[[@B66-jcm-09-00543]\]. Clinicians will need to watch for adverse events, such as nausea, headache and dizziness, which are more frequent than with triple therapy due to the intake of three antimicrobial agents at the same time \[[@B67-jcm-09-00543],[@B69-jcm-09-00543]\].

4.3. Efficacy of Vonoprazan-Containing Triple Therapy {#sec4dot3-jcm-09-00543}
-----------------------------------------------------

High intragastric pH levels during eradication therapy improved eradication rates for *H. pylori* infection \[[@B70-jcm-09-00543],[@B71-jcm-09-00543],[@B72-jcm-09-00543]\]. Vonoprazan (VPZ), a potent new acid secretion inhibitor, inhibits gastric parietal cell potassium ions binding to H^+^/K^+^ -ATPase more potently and more reliably than conventional PPIs, suggesting it may be more effective \[[@B73-jcm-09-00543],[@B74-jcm-09-00543],[@B75-jcm-09-00543]\]. A number of RCTs have compared eradication rates of VPZ-containing triple therapy and conventional PPI-containing triple therapy \[[@B76-jcm-09-00543],[@B77-jcm-09-00543],[@B78-jcm-09-00543]\]. In 2016, a phase III study in 650 *H. pylori*-positive subjects confirmed that the first-line eradication rate for triple therapy containing VPZ, AMPC, and CAM was 92.6%, and thus higher than that for PAC therapy including lansoprazole (75.9%) \[[@B76-jcm-09-00543]\]. A previous meta-analysis also showed that VPZ-containing triple therapy had a significantly higher eradication rate than PAC therapy (88.1% and 72.8%) \[[@B79-jcm-09-00543]\], especially in patients infected with CAM-resistant strains (82.0% vs. 40.0%) \[[@B80-jcm-09-00543]\]. However, in patients infected with CAM-sensitive strains, a meta-analysis showed no significant difference in eradication rates between VPZ-containing triple therapy and PAC therapy (95.3% and 92.8%), suggesting that the efficacy of VPZ-containing triple therapy was limited for patients infected with CAM-resistant strains. Therefore, VPZ-containing triple therapy has potential in populations or regions with well-documented high CAM resistance (more than 15%), such as the MNZ-S/CAM-R and MNZ-R/CAM-R areas. The efficacy of VPZ-containing triple therapy has not yet been compared to that of PAM, bismuth quadruple, and non-bismuth quadruple therapies in regions with high CAM resistance. It has also not yet been shown whether VPZ-based triple therapy containing MNZ has greater efficacy than PAM therapy.

5. Conclusions {#sec5-jcm-09-00543}
==============

In conclusion, eradication rates and adverse event rates of PAC and PAM therapies were found to be equivalent worldwide. However, eradication rates of both regimens were insufficient to eradicate *H. pylori* infection without considering drug resistance in more than 90% of *H. pylori*-positive patients. The results of this meta-analysis suggest that because the efficacy of eradication therapy is based on susceptibility to antimicrobial agents, PAM therapy may have the potential to eradicate \> 90% of *H. pylori* infections in patients infected with MNZ-sensitive strains, whereas the eradication rate of PAC therapy is low even in patients infected with CAM-sensitive strains. The incidence of antimicrobial agent resistance in *H. pylori* is changing among geographic areas, and it is therefore important to periodically reevaluate the efficacy of eradication regimens.
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![Forest plots of overall eradication rates between PAM therapy and PAC therapy in all eligible trials with intention-to-treat analysis (**A**) and per-protocol analysis (**B**) in the random-effects model. The relative risk (RR) for successful eradication between PAC therapy and PAM therapy was similar in the intention-to-treat (ITT) analysis (**A**) and the per-protocol (PP) analysis (**B**). Abbreviations: CI, confidence interval; PAC, proton pump inhibitor (PPI)/amoxicillin/clarithromycin; PAM, PPI/amoxicillin/metronidazole.](jcm-09-00543-g002){#jcm-09-00543-f002}
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![Forest plot of the incidence rate of all adverse events between PAC therapy and PAM therapy in the random effects model. Abbreviation: CI, confidence interval; PAC, proton pump inhibitor (PPI)/amoxicillin/clarithromycin; PAM, PPI/amoxicillin/metronidazole.](jcm-09-00543-g006){#jcm-09-00543-f006}

jcm-09-00543-t001_Table 1

###### 

Characteristics of the studies comparing efficacy of PAC vs. PAM regimens.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                        Year   Country    Patient Number   Age\     Sex\      Regimen of PAC Therapy\                     Duration         Eradication Rate of PAC\   Regimen of PAM Therapy\                      Duration         Eradication Rate of PAM\
                                                                                    (mean)   (M/F)     (Dosing Dose a Day)                                          (ITT/PP)                   (Dosing Dose a Day)                                           (ITT/PP)
  ---------------------------------------------- ------ ---------- ---------------- -------- --------- ------------------------------------------- ---------------- -------------------------- -------------------------------------------- ---------------- --------------------------
  Labenz et al. \[[@B28-jcm-09-00543]\]          1996   Germany    64               NA       NA        OPZ (20), AMPC (1000), CAM (500)            7 days           96.8%/96.8%                OPZ (20), AMPC (1000), MNZ (500)             7 days           84.8%/84.8%

  Lind et al. \[[@B27-jcm-09-00543]\]            1996   Multiple   391              NA       NA        OPZ (20), AMPC (1000), CAM (500)            7 days           85.0%/91.4%                OPZ (20), AMPC (1000), MNZ (400)             7 days           75.8%/81.6%

  Misiewicz et al. \[[@B29-jcm-09-00543]\]       1997   UK         252              48       176/76    LPZ (30), AMPC (1000), CAM (250)            7 days           86.0%/90.4%                LPZ (30), AMPC (1000), MNZ (400)\*           7 days           66.4%/73.5%

  Miyaji et al. \[[@B30-jcm-09-00543]\]          1997   Japan      144              52       NA        PPIs AMPC (500), CAM (200)                  7 days           79.7%/79.7%                PPIs AMPC (500), MNZ (250)                   7 days           85.7%/85.7%

  Pieramico et al. \[[@B31-jcm-09-00543]\]       1997   Italy      119              53       61/58     OPZ (20), AMPC (1000), CAM (500)            7 days           86.2%/92.6%                OPZ (20), AMPC (1000), MNZ (500)             7 days           80.3%/86.0%

  Stack et al. \[[@B32-jcm-09-00543]\]           1997   UK         38               52       28/10     RPZ (20), AMPC (1000), CAM (500)            7 days           94.7%/100.0%               RPZ (20), AMPC (1000), MNZ (400)             7 days           89.5%/88.2%

  Harris et al. \[[@B33-jcm-09-00543]\]          1998   UK         126              47       88/38     PPIs AMPC (1000), CAM (250)                 7 days           85.5%/89.8%                PPIs AMPC (500), MNZ (400)                   7 days           64.1%/76.0%

  Pilotto et al. \[[@B34-jcm-09-00543]\]         1999   Italy      100              77       43/57     LPZ (30), AMPC (1000), CAM (250)            7 days           82.0%/89.1%                LPZ (30), AMPC (1000), MNZ (250)             7 days           80.0%/87.0%

  Pilotto et al. \[[@B35-jcm-09-00543]\]         1999   Italy      78               71       28/50     PAN (40), AMPC (1000), CAM (250)            7 days           85.0%/85.0%                PAN (40), AMPC (1000), MNZ (250)             7 days           78.9%/85.7%

  Savarino et al. \[[@B36-jcm-09-00543]\]        1999   Italy      160              49       86/74     OPZ (20), AMPC (1000), CAM (250)            7 days           57.5%/66.7%                OPZ (20), AMPC (1000), MNZ (500)             7 days           77.5%/88.6%

  Uygun et al. \[[@B37-jcm-09-00543]\]           1999   Turkey     222              39       119/103   OPZ (20), AMPC (1000), CAM (500)            7 days           60.2%/67.1%                OPZ (20), AMPC (1000), MNZ (500)/TNZ (500)   7 days           57.5%/63.6%

  Huang et al. \[[@B38-jcm-09-00543]\]           2000   Taiwan     67               42       37/30     LPZ (30), AMPC (1000), CAM (500)            7 days           89.2%/94.3%                LPZ (30), AMPC (1000), MNZ (500)             7 days           70.0%/77.8%

  Malfertheiner et al. \[[@B39-jcm-09-00543]\]   2003   Germany    336              57       184/152   PAN (40), AMPC (1000), CAM (500)            7 days           66.9%/89.0%                PA (40), AMPC (1000), MNZ (500)              7 days           59.9%/75.8%

  Bhatia et al. \[[@B40-jcm-09-00543]\]          2004   India      146              39       113/33    LPZ (30), AMPC (1000), CAM (500)            14 days          46.1%/64.8%                LPZ (30), AMPC (1000), TNZ (500)             14 days          31.4%/42.3%

  Namiot et al. \[[@B41-jcm-09-00543]\]          2004   Poland     90               42       68/22     OPZ (20), AMPC (1000), CAM (250)            7 days           68.9%/81.6%                OPZ( 20), AMPC (1000), TNZ (500)             7 days           68.9%/77.5%

  Koivisto et al. \[[@B23-jcm-09-00543]\]        2005   Finland    216              56       103/113   LPZ (30), AMPC (1000), CAM (500)            7 days           90.9%/90.9%                LPZ (30), AMPC (1000), MNZ (400)\*           7 days           78.3%/78.3%

  Sun et al. \[[@B42-jcm-09-00543]\]             2005   China      103              51       85/18     OPZ (20), AMPC (1000), CAM (500)            7 days           86.2%/89.3%                OPZ (20), AMPC (1000), MNZ (500)             7 days           82.2%/84.1%

  Sancar et al. \[[@B43-jcm-09-00543]\]          2006   Turkey     35               43       18/17     LPZ (30)/OPZ (20), AMPC (1000), CAM (500)   7, 14 days       83.3%/83.3%                LPZ (30)/OPZ (20), AMPC (1000), MNZ (500)    7, 14 days       50.0%/50.0%

  Namiot et al. \[[@B44-jcm-09-00543]\]          2008   Poland     159              50       106/53    OPZ( 20), AMPC (1000), CAM (250)            7 days           77.4%/80.2%                OPZ (20), AMPC (1000), MNZ (250)             7 days           63.4%/66.7%

  Filipec et al. \[[@B45-jcm-09-00543]\]         2009   Croatia    592              52       335/257   PAN (40), AMPC (1000), CAM (500)            7, 10, 14 days   83.1%/88.1%                PAN (40), AMPC (1000), MNZ (500)             7, 10, 14 days   79.8%/84.0%

  Loghmari et al. \[[@B46-jcm-09-00543]\]        2012   Tunisia    85               40       44/41     OPZ (20), AMPC (1000), CAM (500)            7 days           69.6%/69.6%                OPZ (20), AMPC (1000), MNZ (500)             7 days           48.7%/48.7%

  Lahbabi et al. \[[@B47-jcm-09-00543]\]         2013   Morocco    219              47       105/114   PPIs AMPC (1000), CAM (500)                 7 days           78.3%/79.6%                PPIs AMPC (1000), MNZ (500)                  7 days           70.2%/70.9%

  Nishizawa et al. \[[@B48-jcm-09-00543]\]       2015   Japan      219              47       105/114   PAN (40), AMPC (1000), CAM (500)            14 days          42.0%/48.3%                PAN (40), AMPC (1000), MNZ (500)             14 days          52.0%/54.2%

  Lee et al. \[[@B49-jcm-09-00543]\]             2015   Korea      340              57       209/131   RPZ (20), AMPC (1000), CAM (500)            7 days           64.1%/76.2%                RPZ (20), AMPC (1000), MNZ (750)             7 days           68.8%/84.2%

  Gungor et al. \[[@B50-jcm-09-00543]\]          2015   Turkey     124              61       51/73     RPZ (10), AMPC (750), CAM (400)             7 days           73.3%/77.2%                RPZ (10), AMPC (750), MNZ (250)              7 days           90.6%/93.5%

  Adachi et al. \[[@B17-jcm-09-00543]\]          2017   Japan      140              64       68/72     EPZ (20), AMPC (750), CAM (400)             7 days           70.6%/72.7%                EPZ (20), AMPC (750), MNZ (500)              7 days           91.7%/94.3%

  Mabe et al. \[[@B18-jcm-09-00543]\]            2018   Japan      306              26       157/149   LPZ (30), AMPC (750), CAM (200)             7 days           65.0%/65.7%                LPZ (30), AMPC (750), MNZ (250)              7 days           96.4%/96.9%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AMPC, amoxicillin; CAM, clarithromycin; D, day: EPZ, esomeprazole; LPZ, lansoprazole; MNZ, metronidazole; NA, not available; OPZ, omeprazole; PAC, proton pump inhibitor/amoxicillin/clarithromycin; PAM, proton pump inhibitor/amoxicillin/metronidazole; PAN, pantoprazole; PPI, proton pump inhibitor; RPZ, rabeprazole; TNZ, Tinidazole; UK, United Kingdom.

jcm-09-00543-t002_Table 2

###### 

Adverse effects of PAC and PAM therapy in individual studies.

  Authors                                    PAC   PAM                                                      
  ------------------------------------------ ----- ------- ---- ---- ---- ---- ----- ------- ---- ---- ---- ----
  Lind et al. \[[@B27-jcm-09-00543]\]        234   NA      29   NA   18   2    124   NA      24   NA   11   2
  Misiewicz et al. \[[@B29-jcm-09-00543]\]   121   51.2%   22   NA   2    NA   131   57.3%   19   NA   13   NA
  Pieramico et al. \[[@B31-jcm-09-00543]\]   58    10.3%   2    0    1    0    61    8.2%    1    0    0    1
  Stack et al. \[[@B32-jcm-09-00543]\]       19    NA      9    NA   8    NA   19    NA      11   NA   3    NA
  Harris et al. \[[@B33-jcm-09-00543]\]      62    0.0%    0    0    0    0    64    0.0%    0    0    0    0
  Pilotto et al. \[[@B34-jcm-09-00543]\]     50    14.0%   NA   NA   NA   NA   50    10.0%   NA   NA   NA   NA
  Pilotto et al. \[[@B35-jcm-09-00543]\]     40    10.0%   NA   NA   NA   NA   38    5.3%    NA   NA   NA   NA
  Savarino et al. \[[@B36-jcm-09-00543]\]    80    17.5%   3    1    4    3    80    15.0%   1    2    2    3
  Uygun et al. \[[@B37-jcm-09-00543]\]       79    11.4%   3    0    5    0    121   9.1%    1    2    0    7
  Huang et al. \[[@B38-jcm-09-00543]\]       37    27.0%   3    0    1    3    30    43.3%   2    0    4    3
  Bhatia et al. \[[@B40-jcm-09-00543]\]      76    9.2%    NA   NA   NA   NA   70    21.4%   NA   NA   NA   NA
  Koivisto et al. \[[@B23-jcm-09-00543]\]    110   11.8%   NA   NA   NA   NA   106   9.4%    NA   NA   NA   NA
  Sun et al. \[[@B42-jcm-09-00543]\]         58    10.3%   1    1    0    1    45    11.1%   1    1    2    1
  Filipec et al. \[[@B45-jcm-09-00543]\]     295   NA      13   NA   15   12   297   NA      11   NA   22   26
  Lahbabi et al. \[[@B47-jcm-09-00543]\]     115   27.8%   11   1    11   NA   104   22.1%   9    1    6    NA
  Nishizawa et al. \[[@B48-jcm-09-00543]\]   100   16.0%   11   1    7    0    100   8.0%    9    1    6    0
  Lee et al. \[[@B49-jcm-09-00543]\]         170   50.6%   24   0    28   12   170   54.7%   2    0    10   32
  Gungor et al. \[[@B50-jcm-09-00543]\]      58    22.4%   5    5    1    2    63    17.5%   6    3    0    0
  Mabe et al. \[[@B18-jcm-09-00543]\]        137   16.8%   8    4    4    2    169   17.2%   12   4    4    3

Abbreviations: N, number; NA, not available; PAC, proton pup inhibitor (PPI)/amoxicillin/ clarithromycin; PAM, PPI/amoxicillin/metronidazole.
